Janssen's Imbruvica Demonstrates Significant Survival Outcomes In Older Lymphoma Patients

Primary seven-year data from Janssen's (Johnson & Johnson) Phase III trial of Imbruvica (ibrutinib) in lymphoma demonstrated positive survival outcomes.

The Phase III SHINE study showed the drug's ability to reduce the risk of disease progression by 25% when combined with bendamustine-rituximab (BR) and rituximab in patients with newly diagnosed mantle cell lymphoma (MCL). The results are from participants ages 65 years and older.